Recent Updates
Recently added Catalysts

AS MDI

Phase 2

Asthma | Small molecule | Respiratory |AstraZeneca PLC|Last Updated: Jul 23, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03371459Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With AsthmaPHASE2 COMPLETED 46Dec 29, 2017Mar 26, 2018Jul 23, 20195 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose
At the two study treatment visits, FEV1 (forced expiratory volume in 1 second) will be measured prior to drug administration and 5 times, once at 30 minutes after each of the 5 doses

Forced expiratory volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation

Secondary Endpoints
Baseline-adjusted FEV1 AUC0-6 After the Last Cumulative Dose
Over 6 hours post dose on Day 1
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AS MDIEXPERIMENTALAS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
ProventilACTIVE_COMPARATORProventil 1+1+2+4+8 inhalations of 90 μg per inhalation
Interventions
NameTypeDescription
AS MDIDRUGAS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
ProventilDRUGProventil 1+1+2+4+8 inhalations of 90 μg per inhalation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis * Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to me...

Countries:United States
Unlock Eligibility Criteria